Peptide–Drug Conjugates (PDCs) Market Size, Share & Trends Analysis Report Product Type (Radiopharmaceutical PDCs, Cytotoxic PDCs, Diagnostic PDCs, Emerging PDCs), By Therapeutic Application (Oncology, Neuroendocrine Tumors, Prostate Cancer, Solid Tumors, Hematologic Cancers, Neurological Disorders, Metabolic Diseases, Infectious Diseases), Type, Product, By Region, And By Segment Forecasts, 2025-2034

Report Id: 1351 Pages: 180 Last Updated: 21 April 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Peptide–Drug Conjugates (PDCs) Market

Global Peptide–drug conjugates (PDCs) Market, by Product Type, 

  • Radiopharmaceutical PDCs
  • Cytotoxic PDCs
  • Diagnostic PDCs
  • Emerging PDCs

PDC

Global Peptide–drug conjugates (PDCs) Market, by Therapeutic Application, 

  • Oncology
  • Neuroendocrine Tumors
  • Prostate Cancer
  • Solid Tumors
  • Hematologic Cancers
  • Neurological Disorders
  • Metabolic Diseases
  • Infectious Diseases

Global Peptide–drug conjugates (PDCs) Market, by Product, 

  • OctreoScan
  • Lutathera
  • Pluvicto
  • Illuccix
  • Others

Global Peptide–drug conjugates (PDCs) Market, by Type, 

  • Therapeutic
  • Diagnostic

Global Peptide–drug conjugates (PDCs) Market, by Region, 

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Peptide–drug conjugates (PDCs) Market, by Country, 

  • U.S.
  • Canada

Europe Peptide–drug conjugates (PDCs) Market, by Country,

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Peptide–drug conjugates (PDCs) Market, by Country, 

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Peptide–drug conjugates (PDCs) Market, by Country,

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Peptide–drug conjugates (PDCs) Market, by Country,

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Peptide–Drug Conjugates (PDCs) Market Snapshot

Chapter 4. Global Peptide–Drug Conjugates (PDCs) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Global Peptide–Drug Conjugates (PDCs) Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on PEPTIDE–DRUG CONJUGATES (PDCS) MARKET Industry Trends

Chapter 5. Peptide–Drug Conjugates (PDCs) Market Segmentation 1: By Product Type, Estimates & Trend Analysis
5.1. Market Share By Product Type, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product Type:

5.2.1. Radiopharmaceutical PDCs
5.2.2. Cytotoxic PDCs
5.2.3. Diagnostic PDCs
5.2.4. Emerging PDCs

Chapter 6. Peptide–Drug Conjugates (PDCs) Market Segmentation 2: By Product, Estimates & Trend Analysis
6.1. Market Share By Product, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:

6.2.1. OctreoScan
6.2.2. Lutathera
6.2.3. Pluvicto
6.2.4. Illuccix
6.2.5. Others

Chapter 7. Peptide–Drug Conjugates (PDCs) Market Segmentation 3: By Therapeutic Application, Estimates & Trend Analysis
7.1. Market Share By Therapeutic Application, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:

7.2.1. Oncology
7.2.2. Neuroendocrine Tumors
7.2.3. Prostate Cancer
7.2.4. Solid Tumors
7.2.5. Hematologic Cancers
7.2.6. Neurological Disorders
7.2.7. Metabolic Diseases
7.2.8. Infectious Diseases

Chapter 8. Peptide–Drug Conjugates (PDCs) Market Segmentation 4: By Type, Estimates & Trend Analysis
8.1. Market Share By Type, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Vessel Type:

8.2.1. Therapeutic
8.2.2. Diagnostic

Chapter 9. Peptide–Drug Conjugates (PDCs) Market Segmentation 6: Regional Estimates & Trend Analysis
9.1. Global Peptide–Drug Conjugates (PDCs) Market, Regional Snapshot 2024 & 2034
1.1. North America
1.1.1. North America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
1.1.1.1. United States
1.1.1.2. Canada
1.1.2. North America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2021-2034
1.1.3. North America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product, 2021-2034
1.1.4. North America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Application, 2021-2034
1.1.5. North America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
1.2. Europe
1.2.1. Europe Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
1.2.1.1. Finland
1.2.1.2. UK
1.2.1.3. France
1.2.1.4. Germany
1.2.1.5. Netherland
1.2.1.6. Spain
1.2.1.7. Rest of Europe
1.2.2. Europe Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2021-2034
1.2.3. Europe Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product, 2021-2034
1.2.4. Europe Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Application, 2021-2034
1.2.5. Europe Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
1.3. Asia Pacific
1.3.1. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
1.3.1.1. China
1.3.1.2. Japan
1.3.1.3. South Korea
1.3.1.4. Rest of Asia Pacific
1.3.2. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2021-2034
1.3.3. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product, 2021-2034
1.3.4. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Application, 2021-2034
1.3.5. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
1.3.6. Asia Pacific Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by Cargo Ships, 2021-2034
1.4. Latin America
1.4.1. Latin America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
1.4.1.1. GCC Countries
1.4.1.2. Israel
1.4.1.3. South Africa
1.4.1.4. Rest of Middle East and Africa
1.4.2. Latin America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2021-2034
1.4.3. Latin America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product, 2021-2034
1.4.4. Latin America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Application, 2021-2034
1.4.5. Latin America Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
1.5. Middle East & Africa
1.5.1. Middle East & Africa Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
1.5.1.1. GCC Countries
1.5.1.2. Israel
1.5.1.3. South Africa
1.5.1.4. Rest of Middle East and Africa
1.5.2. Middle East & Africa Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2021-2034
1.5.3. Middle East & Africa Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Product, 2021-2034
1.5.4. Middle East & Africa Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Application, 2021-2034
1.5.5. Middle East & Africa Peptide–Drug Conjugates (PDCs) Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034

Chapter 2. Competitive Landscape
2.1. Major Mergers and Acquisitions/Strategic Alliances
2.2. Company Profiles

2.2.1. Novartis AG

2.2.1.1. Business Overview
2.2.1.2. Key Product/Service
2.2.1.3. Financial Performance
2.2.1.4. Geographical Presence
2.2.1.5. Recent Developments with Business Strategy

2.2.2. AstraZeneca
2.2.3. Bicycle Therapeutics
2.2.4. Cybrexa Therapeutics
2.2.5. Esperance Pharmaceuticals
2.2.6. Oncopeptides AB
2.2.7. Pepgen Corporation
2.2.8. Soricimed Biopharma
2.2.9. Theratechnologies
2.2.10. Pfizer Inc
2.2.11. Validus Pharmaceuticals LLC
2.2.12. Antisense Therapeutics
2.2.13. Midatech Pharma PLC
2.2.14. Ipsen Pharma
2.2.15. Chiasma, Inc.
2.2.16. Peptron, Inc.
2.2.17. CRINETICS PHARMACEUTICALS
2.2.18. Dauntless Pharmaceuticals
2.2.19. Camurus AB
2.2.20. Teva Pharmaceuticals Inc.
2.2.21. Pharmaspur
2.2.22. Aspireo Pharmaceuticals
2.2.23. Ionis Pharmaceuticals Inc
2.2.24. Midatech Pharma Plc
2.2.25. Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
4429
Security Code field cannot be blank!

Frequently Asked Questions

Antisense Therapeutics, Midatech Pharma PLC, Ipsen Pharma, Chiasma, Inc., Peptron, Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Camurus

The Peptide–Drug Conjugates (PDCs) Market is expected to grow at a 18.8 % CAGR during the forecast period for 2025-2034.

The Peptide–Drug Conjugates (PDCs) Market Size is valued at USD 3.80 billion in 2024 and is predicted to reach USD 21.10 billion by the year 2034.

product type, therapeutic application, product, and type are the key segments of the Peptide–Drug Conjugates (PDCs) Market.

North American region is leading the Peptide–Drug Conjugates (PDCs) Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying